Biosimilars 2021 Year in Review

Since the passage of the Biologics Price Competition and Innovation Act (BPCIA), companies, courts, regulatory authorities, legislators, and the markets have been grappling with the emergence of biosimilars and now new interchangeables. The field is constantly changing; keeping abreast of these changes helps stakeholders understand future opportunities.

Life sciences attorneys John Adkisson and Jenny Shmuel provide a comprehensive look at the U.S. biosimilars field in 2021. The webinar highlights:

• The U.S. biosimilars market, including approvals and launches
• FDA announcements and guidance
• Select court cases and appellate guidance
• Trends in IPRs
• Recent relevant legislation

In addition, our hosts identify other developments in the biosimilar space they anticipate in the coming year.

Download a Copy of the Webinar Slides.